Aquestive Therapeutics (NASDAQ:AQST) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a buy rating in a research report report published on Friday morning, Zacks.com reports. Zacks Investment Research currently has $6.00 target price on the stock.

According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States. “

AQST has been the topic of a number of other reports. BMO Capital Markets lowered their price objective on shares of Aquestive Therapeutics from $18.00 to $13.00 in a report on Monday, September 28th. Royal Bank of Canada lowered their price objective on shares of Aquestive Therapeutics from $8.00 to $7.00 and set an outperform rating on the stock in a report on Monday, September 28th. HC Wainwright lowered their price objective on shares of Aquestive Therapeutics from $15.00 to $14.00 and set a buy rating on the stock in a report on Monday, September 28th. Lake Street Capital lifted their price objective on shares of Aquestive Therapeutics from $7.00 to $10.00 and gave the company a buy rating in a report on Monday, September 28th. Finally, JMP Securities lowered their price objective on shares of Aquestive Therapeutics from $23.00 to $17.00 and set an outperform rating on the stock in a report on Monday, September 28th. Nine analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus price target of $14.29.

Shares of AQST stock opened at $5.35 on Friday. The company has a market capitalization of $179.87 million, a P/E ratio of -3.50 and a beta of 3.87. The company’s 50 day moving average price is $6.75 and its two-hundred day moving average price is $6.20. Aquestive Therapeutics has a 52 week low of $1.41 and a 52 week high of $9.47.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Monday, November 9th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.03). The business had revenue of $8.26 million for the quarter, compared to analysts’ expectations of $8.52 million. On average, sell-side analysts forecast that Aquestive Therapeutics will post -1.54 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund bought a new position in shares of Aquestive Therapeutics in the second quarter valued at $91,000. Bank of New York Mellon Corp bought a new position in Aquestive Therapeutics during the second quarter worth $288,000. American International Group Inc. bought a new position in Aquestive Therapeutics during the second quarter worth $59,000. Engineers Gate Manager LP bought a new position in Aquestive Therapeutics during the second quarter worth $126,000. Finally, State Board of Administration of Florida Retirement System bought a new position in Aquestive Therapeutics during the second quarter worth $62,000. 53.80% of the stock is owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc, a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

See Also: Market Perform

Get a free copy of the Zacks research report on Aquestive Therapeutics (AQST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.